Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab

被引:82
作者
Jones, Lee W.
Haykowsky, Mark
Peddle, Carolyn J.
Joy, Anil A.
Pituskin, Edith N.
Tkachuk, Linda M.
Courneya, Kerry S.
Slamon, Dennis J.
Mackey, John R.
机构
[1] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[2] Univ Alberta, Fac Phys Educ, Edmonton, AB T6G 2M7, Canada
[3] Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada
[4] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
关键词
D O I
10.1158/1055-9965.EPI-06-0870
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the cardiovascular risk profile of a subset of patients with early-stage breast cancer treated with adjuvant taxane-anthracycline-containing chemotherapy and/or trastuzumab (Herceptin). Experimental Design: Twenty-six patients with breast cancer (mean, 20 months postchemotherapy) and 10 healthy age-matched women were studied. We measured 14 metabolic and vascular established cardiovascular disease (CVD) risk factors, body mass index, cardiorespiratory fitness, and left ventricular systolic function. All assessments were done within a 14-day period. Results: Cardiac abnormalities were suggested by left ventricular ejection fraction (LVEF) < 50% in 8% of patients, LVEF remained > 10% below pretreatment values in 38%, whereas 50% presented with resting sinus tachycardia. Brain natriuretic peptide was significantly elevated in 40% of patients and was correlated with LVEF (r = -0.72, P = < 0.001). For the majority of CVD risk factors, similar proportions of patients and controls (35-60%) were classified as "undesirable." A significantly higher proportion of patients were classified with low cardiorespiratory fitness (46% versus 0%, P < 0.01), being overweight/obese (72% versus 50%, P < 0.05), and having resting sinus tachycardia (50% versus 0%, P < 0.01) compared with controls. Cardiorespiratory fitness and body mass index were correlated with CVD risk factors (r = -0.64 to 0.63, P < 0.05; r = -0.63 to 0.67, P < 0.05, respectively). Exploratory analyses revealed several differences between CVD risk factors based on chemotherapy regimen. Conclusion: Breast cancer survivors treated with adjuvant chemotherapy are at a higher risk of developing late-occurring CVD than age-matched controls due to direct and indirect treatment-related toxicity.
引用
收藏
页码:1026 / 1031
页数:6
相关论文
共 19 条
[11]   N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease [J].
Kragelund, C ;
Gronning, B ;
Kober, L ;
Hildebrandt, P ;
Steffensen, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (07) :666-675
[12]   Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men [J].
Lowe, LP ;
Greenland, P ;
Ruth, KJ ;
Dyer, AR ;
Stamler, R ;
Stamler, J .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (18) :2007-2014
[13]   Walking compared with vigorous exercise for the prevention of cardiovascular events in women [J].
Manson, JE ;
Greenland, P ;
LaCroix, AZ ;
Stefanick, ML ;
Mouton, CP ;
Oberman, A ;
Perri, MG ;
Sheps, DS ;
Pettinger, MB ;
Siscovick, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (10) :716-725
[14]   Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients [J].
Meinardi, MT ;
van Veldhuisen, DJ ;
Gietema, JA ;
Dolsma, WV ;
Boomsma, F ;
van den Berg, MP ;
Volkers, C ;
Haaksma, J ;
de Vries, EGE ;
Sleijfer, DT ;
van der Graaf, WTA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2746-2753
[15]   Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial [J].
Perez, EA ;
Suman, VJ ;
Davidson, NE ;
Kaufman, PA ;
Martino, S ;
Dakhil, SR ;
Ingle, JN ;
Rodeheffer, RJ ;
Gersh, BJ ;
Jaffe, AS .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3700-3704
[16]   Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].
Piccart-Gebhart, MJ ;
Procter, M ;
Leyland-Jones, B ;
Goldhirsch, A ;
Untch, M ;
Smith, I ;
Gianni, L ;
Baselga, J ;
Bell, R ;
Jackisch, C ;
Cameron, D ;
Dowsett, M ;
Barrios, CH ;
Steger, G ;
Huang, CS ;
Andersson, M ;
Inbar, M ;
Lichinitser, M ;
Láng, I ;
Nitz, U ;
Iwata, H ;
Thomssen, C ;
Lohrisch, C ;
Suter, TM ;
Ruschoff, J ;
Süto, T ;
Greatorex, V ;
Ward, C ;
Straehle, C ;
McFadden, E ;
Dolci, MS ;
Gelber, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672
[17]   Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].
Romond, EH ;
Perez, EA ;
Bryant, J ;
Suman, VJ ;
Geyer, CE ;
Davidson, NE ;
Tan-Chiu, E ;
Martino, S ;
Paik, S ;
Kaufman, PA ;
Swain, SM ;
Pisansky, TM ;
Fehrenbacher, L ;
Kutteh, LA ;
Vogel, VG ;
Visscher, DW ;
Yothers, G ;
Jenkins, RB ;
Brown, AM ;
Dakhil, SR ;
Mamounas, EP ;
Lingle, WL ;
Klein, PM ;
Ingle, JN ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684
[18]  
Slamon D, 2006, BREAST CANC RES TREA
[19]   Cardiovascular complications of cancer therapy - Diagnosis, pathogenesis, and management [J].
Yeh, ETH ;
Tong, AT ;
Lenihan, DJ ;
Yusuf, SW ;
Swafford, J ;
Champion, C ;
Durand, JB ;
Gibbs, H ;
Zafarmand, AA ;
Ewer, MS .
CIRCULATION, 2004, 109 (25) :3122-3131